Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary and secondary objectives of this study are:
Primary: To evaluate stem-cell-mobilization in subjects with diabetic neuropathy receiving
SB-509. Stem cell mobilization will be assessed by evaluating the presence of stem cells
circulating in peripheral blood.
Secondary: To evaluate the safety of SB-509 in subjects treated with SB-509 with diabetic
neuropathy; and to compare the effect of SB-509 versus placebo on a pre-defined
multi-endpoint analysis that includes visual analog scale for pain intensity (VASPI), total
neuropathy score (TNS), evoked nerve conduction velocity (NCV) and quantitative sensory
testing (QST)